Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Adrianna Hyams

Nurse Practitioner Newburgh, IN Nurse Practitioner

NPI 1386179695 CMS profile 11166550

3800 Venetian Way, Ste 200, Newburgh, IN 47630

Open in the dashboard

General payments

$6,108

391 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adrianna Hyams of Newburgh, IN is reported in the CMS Open Payments database as having received $6,108 across 391 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,271 114
2024 General $99 6
2023 General $1,281 73
2022 General $1,577 115
2021 General $881 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adrianna Hyams
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Adrianna Hyams were reported at $2,271. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Adrianna Hyams Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $881 $135 $40–$426 $132
2022 $1,577 $152 $48–$470 $149
2023 $1,281 $166 $54–$529 $160
2024 $99 $173 $55–$556 $164
2025 $2,271 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,586 132 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $642 41 payments
  3. Celgene Corporation $600 46 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $279 17 payments
  5. Teva Pharmaceuticals USA, Inc. $263 11 payments
  6. Gilead Sciences, Inc. $240 18 payments
  7. Janssen Biotech, Inc. $207 11 payments
  8. Eisai Inc. $190 6 payments
  9. Pfizer Inc. $180 14 payments
  10. SK Life Science, Inc. $178 8 payments
  11. Other $1,743 87 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,948 389 payments
  2. Education $160 2 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $600 36 payments
  2. ZEPOSIA $569 44 payments
  3. XIFAXAN $368 27 payments
  4. TRULANCE $289 15 payments
  5. ENTYVIO $256 15 payments
  6. HUMIRA $252 40 payments
  7. UBRELVY $241 21 payments
  8. SKYRIZI $238 15 payments
  9. STELARA $207 11 payments
  10. PLENVU $191 14 payments
  11. Other $3,291 196 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

103

Median for Nurse Practitioner: 389

Drug cost

$748

Median for Nurse Practitioner: $21,885

Branded share of claims

10.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cefdinir Generic 12 $230
Fluticasone Propionate Generic 15 $141
Doxycycline Monohydrate Generic 18 $135
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 11 $120
Cephalexin Generic 13 $61
Amoxicillin Generic 19 $35
Prednisone Generic 15 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$11,198

Medicare's payments for the services billed

Medicare patients

134

Average age 70

Services billed

260

85 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Ischemic heart disease 31%
Diabetes 29%
Depression 25%
Chronic kidney disease 20%
COPD 18%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPOSIA
  • Celgene Corporation $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

391 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record